Non-flavonoid Polyphenols in Osteoporosis: Preclinical Evidence

Research output: Contribution to journalReview articlepeer-review


The development of progressive osteopenia and osteoporosis (OP) is due to the imbalance between bone resorption and bone formation, determining a lower bone resistance, major risks of fractures, with consequent pain and functional limitations. Flavonoids, a class of polyphenols, have been extensively studied for their therapeutic activities against bone resorption, but less attention has been given to a whole series of molecules belonging to the polyphenolic compounds. However, these classes have begun to be studied for the treatment of OP. In this systematic review, comprehensive information is provided on non-flavonoid polyphenolic compounds, and we highlight pathways implicated in the action of these molecules that act often epigenetically, and their possible use for OP treatment and prevention.

Original languageEnglish
Pages (from-to)515-529
Number of pages15
JournalTrends in Endocrinology and Metabolism
Issue number7
Early online dateApr 21 2021
Publication statusPublished - Jul 2021


  • bone erosive diseases
  • epigenetics
  • osteoclast
  • osteoporosis
  • polyphenolic compounds


Dive into the research topics of 'Non-flavonoid Polyphenols in Osteoporosis: Preclinical Evidence'. Together they form a unique fingerprint.

Cite this